Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Melanoma

Skin Neoplasms

Neoplasm Metastasis

Nevus

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevi and Melanomas

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Vaccines

Immunomodulating Agents

Allovectin-7®

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

Treatment - If you take part in this trial you will be treated for about 10 weeks. You will receive an injection of Allovectin-7® by needle, directly into one or more selected tumors once a week for the first six weeks. The injections may be given in a doctor's office. During a four-week observation period, your disease will be measured to see if the treatment is working. This will be done by general physical exams and scans (such as X-ray scans). Patients who show no sign of disease progression may be offered an option to repeat this treatment course.

Phase II Trial of Allovectin-7® for Metastatic Melanoma

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

Vical

Dmitri D. Kharkevitch, MD, PhD

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Carcinoma

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Laryngeal Diseases

Otorhinolaryngologic Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms, Squamous Cell

Oral Squamous Cell Carcinoma

Tongue Cancer

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Treatment - If you take part in this trial you will be treated for about four weeks. You will receive an injection of Allovectin-7® by needle, directly into your tumor. This will be repeated 14 days later. The injections may be given in a doctor's office. A week later, you will undergo surgery to remove the tumor. Your tumor will be measured before Allovectin-7® treatment and before surgery to see if Allovectin-7® was effective in shrinking it. This will be done by general physical exams and scans (such as X-ray scans). There will also be tests on the removed tumor to see if Allovectin-7® helped to boost the immune system to attack the cancer.

Phase II Trial of Allovectin-7® for Head and Neck Cancer

Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase II Trial of Allovectin-7® for Metastatic Melanoma	NCT00044356	Melanoma Metastatic Mela... Malignant Melan... Skin Cancer	Allovectin-7®	18 Years -	Vical
Phase II Trial of Allovectin-7® for Head and Neck Cancer	NCT00050388	Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th...	Allovectin-7®	18 Years -	Vical

Spots Global Cancer Trial Database for cancer research